CENTOGENE N.V. (Nasdaq: CNTG) (the “Company”), the essential life
science partner for data-driven answers in rare and
neurodegenerative diseases, today announced the publication in
Science of research on human pre-T cell receptor alpha (pre-TCRα)
deficiency, a condition that often results in infection,
lymphoproliferation, and autoimmune conditions, and its effect on
human immunity.
The research, conducted in collaboration with the Laboratory of
Human Genetics of Infectious Diseases at Institut Imagine and
researchers around the world, analyzed the function of αβ and γδ T
lymphocytes, two lineages of adaptive immunity in vertebrates, in
particular the essential role of the pre-TCRα chain in αβ T cell
development. The study revealed that complete pre-TCRα deficiency
is rare in humans and less severe than anticipated. Clinical
manifestations, when present, often do not appear until adulthood,
suggesting a noncanonical pathway that can rescue αβ T cell
development. Researchers also found that a partial form of pre-TCRα
deficiency is less rare than anticipated, affecting about 1 in
4,000 individuals in South Asia and the Middle East, and can lead
to autoimmunity with incomplete penetrance.
Prof. Peter Bauer, Chief Medical and Genomic Officer at
CENTOGENE, said, "This research advances our understanding of
pre-TCRα deficiency significantly. The paper in Science, which just
so happens to come out on Rare Disease Day, underlines that while a
variant or a condition may be considered rare, in totality, the
number of patients affected can be surprisingly high. Our study
shows that such deficiencies and patients are somehow linked, and
with each insight, we are closer to further understanding human
health and ultimately the path to life-changing answers for
patients.”
CENTOGENE played a pivotal role in the investigation by
conducting an in-depth analysis of the CENTOGENE Biodatabank, the
world’s largest real-world integrated multiomic data repository in
rare and neurodegenerative diseases. In analyzing genomic and
phenomic data, CENTOGENE researchers helped establish the
association between partial pre-TCRα deficiency and autoimmunity,
with a higher prevalence than initially expected.
Christian Beetz, Senior Director Genomic Innovation at
CENTOGENE, added, “Until now, the impact of pre-TCRα deficiency has
been largely unknown. By leveraging our rich data through genomic
and phenotypic analyses, we have been able to understand variants
and the effects they have at a whole new level, which will help us
diagnose and treat patients better in the future. This is what we
are striving for every day.”
“The study results highlight what cross-institutional
collaboration can achieve,” added Christian Ganoza, Senior
Scientist Genomic Innovation at CENTOGENE. “By partnering with Dr.
Vivien Béziat and Dr. Jean-Laurent Casanova of the Laboratory of
Human Genetics of Infectious Diseases and working together with
leading institutions around the world, we have been able to combine
our insights to establish a deeper understanding of pre-TCRα
deficiency, which wouldn’t have been possible otherwise.
Critically, the depth and breadth of the CENTOGENE Biodatabank
provided the power to confirm the genotype-phenotype association in
an independent real-world cohort, and our CENTOGENE team is proud
to have been a part of this.”
To read the full study, visit:
https://bit.ly/centogene-science-publication
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
800,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 285 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “potential,” “predict,” “objective” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, the possibility that no strategic alternatives or trading
market will be available to CENTOGENE, negative economic and
geopolitical conditions and instability and volatility in the
worldwide financial markets, possible changes in current and
proposed legislation, regulations and governmental policies,
pressures from increasing competition and consolidation in our
industry, the expense and uncertainty of regulatory approval,
including from the U.S. Food and Drug Administration, our reliance
on third parties and collaboration partners, including our ability
to manage growth, execute our business strategy and enter into new
client relationships, our dependency on the rare disease industry,
our ability to manage international expansion, our reliance on key
personnel, our reliance on intellectual property protection,
fluctuations of our operating results due to the effect of exchange
rates, our ability to streamline cash usage, our continued ongoing
compliance with covenants linked to financial instruments, our
requirement for additional financing, and our ability to continue
as a going concern, or other factors. For further information on
the risks and uncertainties that could cause actual results to
differ from those expressed in these forward-looking statements, as
well as risks relating to CENTOGENE’s business in general, see
CENTOGENE’s risk factors set forth in CENTOGENE’s Form 20-F filed
on May 16, 2023, with the Securities and Exchange Commission (the
“SEC”) and subsequent filings with the SEC. Any forward-looking
statements contained in this press release speak only as of the
date hereof, and CENTOGENE specifically disclaims any obligation to
update any forward-looking statement, whether as a result of new
information, future events, or otherwise.
CONTACT
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Apr 2024 to May 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From May 2023 to May 2024